Source comparison
Sermorelin vs. Other GH Secretagogues: Clinical Comparison
Sermorelin Acetate GHRH analog. Binds pituitary GHRH receptor 8–12 minutes Subcutaneous injection (200–500 mcg before bed) None. Preserves pulsatile secretion Compounded under 503B or research-grade Ipamorelin Ghrelin mimetic. Binds GHSR1a receptor 2 hours Sub
This comparison does not assign a generated winner or score.
- Sermorelin Acetate
- GHRH analog. Binds pituitary GHRH receptor
- 8–12 minutes
- Subcutaneous injection (200–500 mcg before bed)
- None. Preserves pulsatile secretion
- Compounded under 503B or research-grade
- Ipamorelin
- Ghrelin mimetic. Binds GHSR1a receptor
- 2 hours
- Subcutaneous injection (200–300 mcg)
- Minimal. Selective GH release without cortisol/prolactin elevation
- Research-grade only
- CJC-1295 (DAC)
- Modified GHRH analog with drug affinity complex
- 6–8 days
- Subcutaneous injection (2 mg weekly)
- Moderate. Prolonged GH elevation flattens pulsatility
- MK-677 (Ibutamoren)
- Oral ghrelin receptor agonist
- 24 hours
- Oral tablet (10–25 mg daily)
- Moderate. Continuous receptor activation may desensitize signaling
- Research-grade; investigational new drug
- Exogenous HGH (Somatropin)
- Direct GH replacement
- 3–4 hours (pharmacologic dosing)
- Subcutaneous injection (0.3–1.0 IU daily)
- High. Suppresses endogenous secretion and causes pituitary atrophy
- FDA-approved for specific indications (not anti-aging)
- Professional Assessment
- Sermorelin preserves natural pulsatility and carries the lowest suppression risk. Ideal for aging patients seeking GH restoration without pituitary shutdown. Ipamorelin offers synergy when stacked with sermorelin (CJC-1295 without DAC is often used instead of sermorelin in research stacks). MK-677 provides oral convenience but continuous receptor activation raises concerns about long-term desensitization. Exogenous HGH remains the most potent option but carries the highest metabolic and regulatory risk.